Biogen Inc. (BIIB)

$258.675

+0.85

(+0.33%)▲

Live

Insights on Biogen Inc.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 2.54B → 2.45B (in $), with an average decrease of 1.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 387.9M → 591.6M (in $), with an average increase of 34.4% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 65.0% return, outperforming this stock by 67.4%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 272.2% return, outperforming this stock by 280.9%

Performance

  • $256.83
    $259.23
    $258.68
    downward going graph

    0.72%

    Downside

    Day's Volatility :0.93%

    Upside

    0.21%

    downward going graph
  • $250.31
    $319.76
    $258.68
    downward going graph

    3.24%

    Downside

    52 Weeks Volatility :21.72%

    Upside

    19.1%

    downward going graph

Returns

PeriodBiogen Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-8.61%
-1.3%
-2.9%
6 Months
-5.9%
1.8%
10.7%
1 Year
-2.44%
5.6%
22.9%
3 Years
-8.68%
24.9%
19.1%

Highlights

Market Capitalization
37.3B
Book Value
$99.91
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
18.55
PE Ratio
13.88
PEG Ratio
36.19
Wall Street Target Price
333.66
Profit Margin
26.72%
Operating Margin TTM
26.24%
Return On Assets TTM
6.51%
Return On Equity TTM
20.25%
Revenue TTM
10.0B
Revenue Per Share TTM
69.08
Quarterly Revenue Growth YOY
-5.1%
Gross Profit TTM
7.9B
EBITDA
3.1B
Diluted Eps TTM
18.55
Quarterly Earnings Growth YOY
-0.44
EPS Estimate Current Year
15.46
EPS Estimate Next Year
17.04
EPS Estimate Current Quarter
3.77
EPS Estimate Next Quarter
4.08

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 40 Wall street analysts offering stock ratings for Biogen Inc.(by analysts ranked 0 to 5 stars)
Based on 40 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
29
28
25
Hold
11
12
15
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 28.99%

Current $258.68
Target $333.66

Company Financials

FY17Y/Y Change
Revenue
12.3B
↑ 7.21%
Net Income
2.5B
↓ 31.43%
Net Profit Margin
20.69%
↓ 11.65%
FY18Y/Y Change
Revenue
13.5B
↑ 9.61%
Net Income
4.4B
↑ 74.5%
Net Profit Margin
32.93%
↑ 12.24%
FY19Y/Y Change
Revenue
14.4B
↑ 6.88%
Net Income
5.9B
↑ 32.9%
Net Profit Margin
40.96%
↑ 8.03%
FY20Y/Y Change
Revenue
13.4B
↓ 6.49%
Net Income
4.0B
↓ 32.06%
Net Profit Margin
29.76%
↓ 11.2%
FY21Y/Y Change
Revenue
11.0B
↓ 18.32%
Net Income
1.6B
↓ 61.1%
Net Profit Margin
14.17%
↓ 15.59%
FY22Y/Y Change
Revenue
10.2B
↓ 7.36%
Net Income
3.0B
↑ 95.8%
Net Profit Margin
29.95%
↑ 15.78%
Q1 FY22Q/Q Change
Revenue
2.5B
↓ 7.39%
Net Income
303.8M
↓ 17.49%
Net Profit Margin
12.0%
↓ 1.47%
Q2 FY22Q/Q Change
Revenue
2.6B
↑ 2.26%
Net Income
1.1B
↑ 248.26%
Net Profit Margin
40.86%
↑ 28.86%
Q3 FY22Q/Q Change
Revenue
2.5B
↓ 3.11%
Net Income
1.1B
↑ 7.25%
Net Profit Margin
45.23%
↑ 4.37%
Q4 FY22Q/Q Change
Revenue
2.5B
↑ 1.42%
Net Income
550.4M
↓ 51.49%
Net Profit Margin
21.64%
↓ 23.59%
Q1 FY23Q/Q Change
Revenue
2.5B
↓ 3.18%
Net Income
387.9M
↓ 29.52%
Net Profit Margin
15.75%
↓ 5.89%
Q2 FY23Q/Q Change
Revenue
2.5B
↓ 0.28%
Net Income
591.6M
↑ 52.51%
Net Profit Margin
24.09%
↑ 8.34%
FY17Y/Y Change
Total Assets
23.7B
↑ 3.39%
Total Liabilities
11.1B
↑ 2.85%
FY18Y/Y Change
Total Assets
25.3B
↑ 6.92%
Total Liabilities
12.3B
↑ 10.88%
FY19Y/Y Change
Total Assets
27.2B
↑ 7.69%
Total Liabilities
13.9B
↑ 13.36%
FY20Y/Y Change
Total Assets
24.6B
↓ 9.6%
Total Liabilities
13.9B
↑ 0.27%
FY21Y/Y Change
Total Assets
23.9B
↓ 3.01%
Total Liabilities
12.9B
↓ 7.29%
FY22Y/Y Change
Total Assets
24.6B
↑ 2.83%
Total Liabilities
10.2B
↓ 20.87%
Q1 FY22Q/Q Change
Total Assets
23.6B
↓ 1.1%
Total Liabilities
12.4B
↓ 4.06%
Q2 FY22Q/Q Change
Total Assets
25.1B
↑ 6.21%
Total Liabilities
13.2B
↑ 6.65%
Q3 FY22Q/Q Change
Total Assets
24.9B
↓ 0.91%
Total Liabilities
12.1B
↓ 8.55%
Q4 FY22Q/Q Change
Total Assets
24.6B
↓ 1.21%
Total Liabilities
10.2B
↓ 15.44%
Q1 FY23Q/Q Change
Total Assets
24.6B
↑ 0.18%
Total Liabilities
10.8B
↑ 5.77%
Q2 FY23Q/Q Change
Total Assets
25.2B
↑ 2.27%
Total Liabilities
10.7B
↓ 1.06%
FY17Y/Y Change
Operating Cash Flow
4.6B
↑ 0.63%
Investing Cash Flow
-3.0B
↑ 19.25%
Financing Cash Flow
-2.4B
↑ 140.94%
FY18Y/Y Change
Operating Cash Flow
6.2B
↑ 35.96%
Investing Cash Flow
-2.0B
↓ 30.94%
Financing Cash Flow
-4.5B
↑ 87.9%
FY19Y/Y Change
Operating Cash Flow
7.1B
↑ 14.4%
Investing Cash Flow
470.5M
↓ 122.99%
Financing Cash Flow
-5.9B
↑ 31.05%
FY20Y/Y Change
Operating Cash Flow
4.2B
↓ 40.25%
Investing Cash Flow
-608.6M
↓ 229.35%
Financing Cash Flow
-5.3B
↓ 10.03%
FY21Y/Y Change
Operating Cash Flow
3.6B
↓ 13.95%
Investing Cash Flow
-563.7M
↓ 7.38%
Financing Cash Flow
-2.1B
↓ 60.43%
Q1 FY22Q/Q Change
Operating Cash Flow
161.8M
↓ 80.7%
Investing Cash Flow
-648.0M
↑ 474.98%
Financing Cash Flow
-16.5M
↓ 268.37%
Q2 FY22Q/Q Change
Operating Cash Flow
736.5M
↑ 355.19%
Investing Cash Flow
693.5M
↓ 207.02%
Financing Cash Flow
-471.5M
↑ 2757.58%
Q3 FY22Q/Q Change
Operating Cash Flow
661.0M
↓ 10.25%
Investing Cash Flow
1.7B
↑ 141.12%
Financing Cash Flow
-1.3B
↑ 165.51%

Technicals Summary

Sell

Neutral

Buy

Biogen Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biogen Inc.
Biogen Inc.
-3.79%
-5.9%
-2.44%
-8.68%
-26.87%
Eli Lilly And Company
Eli Lilly And Company
-1.71%
62.1%
64.98%
272.25%
405.99%
Johnson & Johnson
Johnson & Johnson
-4.52%
2.33%
-4.65%
6.68%
12.31%
Merck & Co. Inc.
Merck & Co. Inc.
-5.17%
-0.59%
20.38%
27.35%
45.81%
Abbvie Inc.
Abbvie Inc.
3.16%
-3.64%
6.68%
75.22%
60.26%
Pfizer Inc.
Pfizer Inc.
-11.23%
-20.27%
-27.33%
-11.28%
-27.51%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biogen Inc.
Biogen Inc.
13.88
13.88
36.19
15.46
0.2
0.07
0.0
99.91
Eli Lilly And Company
Eli Lilly And Company
76.25
76.25
2.18
8.92
0.66
0.1
0.01
12.3
Johnson & Johnson
Johnson & Johnson
32.06
32.06
3.79
9.47
0.17
0.09
0.03
28.92
Merck & Co. Inc.
Merck & Co. Inc.
85.2
85.2
1.36
2.86
0.08
0.05
0.03
15.24
Abbvie Inc.
Abbvie Inc.
31.33
31.33
1.28
11.05
0.63
0.09
0.04
7.29
Pfizer Inc.
Pfizer Inc.
8.54
8.54
1.17
3.12
0.23
0.08
0.05
17.54
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biogen Inc.
Biogen Inc.
Buy
$37.3B
-26.87%
13.88
26.72%
Eli Lilly And Company
Eli Lilly And Company
Buy
$521.9B
405.99%
76.25
22.01%
Johnson & Johnson
Johnson & Johnson
Hold
$378.3B
12.31%
32.06
13.35%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$263.7B
45.81%
85.2
5.34%
Abbvie Inc.
Abbvie Inc.
Buy
$268.7B
60.26%
31.33
15.5%
Pfizer Inc.
Pfizer Inc.
Hold
$181.2B
-27.51%
8.54
27.55%

Institutional Holdings

  • PRIMECAP Management Company

    11.07%

  • BlackRock Inc

    9.71%

  • Vanguard Group Inc

    8.42%

  • State Street Corporation

    4.75%

  • Wellington Management Company LLP

    3.69%

  • JPMorgan Chase & Co

    3.09%

Company Information

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili

Organization
Biogen Inc.
Employees
8725
CEO
Mr. Michael R. McDonnell CPA
Industry
Health Technology

Discover More

FAQs